1. Aboobacker S, Kurn H, Al Aboud AM. Secukinumab. 2021 Jun 29.Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 30725776.
2. Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16. PMID: 29344327; PMCID: PMC5761942.
3. Campanati A, Marani A, Martina E, et al. Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2021 Oct 21;9(11):1511. doi: 10.3390/biomedicines9111511. PMID: 34829740; PMCID: PMC8615182.
4. Nair PA, Badri T. Psoriasis. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK448194/
5. Novianto E, Meisyah E, Budianti WK. Alur Tatalaksana Psoriasis Vulgaris di Indonesia. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia. 2019;1-13.
6. Yost J, Gudjonsson JE. The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. F1000 Med Rep. 2009 May 8;1:30. doi: 10.3410/M1-30. PMID: 20948750; PMCID: PMC2924720.
7. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514. doi: 10.1111/jdv.14878. Epub 2018 Mar 22. PMID: 29444376; PMCID: PMC6175198.
8. Secukinumab: Indication, Dosage, Side Effect, Precaution | MIMS Indonesia. Mims.com. 2021. https://www.mims.com/indonesia/drug/info/secukinumab?mtype=generic
9. Lebwohl M., Deodhar A., Griffiths CEM., et al. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. British Journal of Dermatology. April 2021. https://doi.org/10.1111/bjd.20136
10. Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies. Drugs Aging. 2018 Feb;35(2):135-144. doi: 10.1007/s40266-018-0520-z. PMID: 29404966; PMCID: PMC5847154.
11. Igarashi A, Igarashi A, Graham C, Gilloteau I, Tani Y. Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. Journal of Medical Economics. 2018;22(1):7-15.
12. FraizeronTM (secukinumab). Leaflet. Disetujui oleh BPOM 14 Februari 2022. EREG 100005VR12200010.